It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lean muscle mass (LMM) is an important aspect of human health. Temporalis muscle thickness is a promising LMM marker but has had limited utility due to its unknown normal growth trajectory and reference ranges and lack of standardized measurement. Here, we develop an automated deep learning pipeline to accurately measure temporalis muscle thickness (iTMT) from routine brain magnetic resonance imaging (MRI). We apply iTMT to 23,876 MRIs of healthy subjects, ages 4 through 35, and generate sex-specific iTMT normal growth charts with percentiles. We find that iTMT was associated with specific physiologic traits, including caloric intake, physical activity, sex hormone levels, and presence of malignancy. We validate iTMT across multiple demographic groups and in children with brain tumors and demonstrate feasibility for individualized longitudinal monitoring. The iTMT pipeline provides unprecedented insights into temporalis muscle growth during human development and enables the use of LMM tracking to inform clinical decision-making.
Temporalis muscle thickness is a promising marker of lean muscle mass but has had limited utility due to its unknown normal growth trajectory and lack of standardized measurement. Here, the authors develop an automated deep learning pipeline to accurately measure temporalis muscle thickness from routine brain magnetic resonance imaging.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Harvard Medical School, Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Harvard Medical School, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Dana-Farber Cancer Institute, Department of Data Science, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
5 Harvard Medical School, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Michigan State University, East Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2150 1785)
6 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Boston Children’s Hospital, Department of Radiology, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438)
7 Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.239552.a) (ISNI:0000 0001 0680 8770); University of Pennsylvania, Pennsylvania, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
8 University of California, Department of Neurology, Neurosurgery and Pediatrics, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
9 Harvard Medical School, Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Maastricht University, Department of Radiology and Nuclear Medicine, CARIM & GROW, Maastricht, the Netherlands (GRID:grid.5012.6) (ISNI:0000 0001 0481 6099)